PMID- 34311984
OWN - NLM
STAT- MEDLINE
DCOM- 20220809
LR  - 20220809
IS  - 1535-6280 (Electronic)
IS  - 0146-2806 (Linking)
VI  - 47
IP  - 9
DP  - 2022 Sep
TI  - Outcomes With sGC Therapy in Patients With HFpEF: A Meta-Analysis of Prior 
      Trials.
PG  - 100924
LID - S0146-2806(21)00139-0 [pii]
LID - 10.1016/j.cpcardiol.2021.100924 [doi]
AB  - Soluble guanylate cyclase (sGC) agents have been shown to have possible 
      beneficial effects in heart failure treatment. Unfortunately, the role of sGC in 
      HFpEF has not been shown to be efficacious based on recent trials. The CAPACITY 
      HFpEF and VITALITY-HFpEF trials independently showed that sGC does not improve 
      6-minute walk test (6MWT) distance or the Kansas City Cardiomyopathy 
      Questionnaire (KCCQ) physical limitation score (PLS). The objective of this study 
      was to analyze current data on the 6MWT and KCCQ PLS score from trials that 
      included patients with HFpEF treated with sGC. Using MEDLINE and Cochrane 
      databases, meta-analysis and systematic review was performed looking at data in 
      the CAPACITY HFpEF and VITALITY-HFpEF trials.  For safety analysis we evaluated 
      serious adverse events between the CAPACITY HFpEF, VITALITY-HFpEF, 
      SOCRATES-PRESERVED, and DILATE-1trials. A total of 2 trials were analyzed to 
      assess 6MWT and KCCQ score. The total number of combined patients from both 
      trials assessing 6MWT distance in sGC vs placebo therapy were 620 with 309 in the 
      treatment group and 311 in the placebo group. The total number of combined 
      patients from both trials assessing KCCQ score outcomes were 583 with 280 in the 
      treatment group and 303 in the placebo group. A total of 4 trials were evaluated 
      for safety analysis with a total of 987 patients with 529 in the treatment group 
      and 458 in the placebo group. The analysis did not demonstrate significant 
      difference in 6MWT (P = 0.97), KCCQ PLS (P = 0.83), or serious adverse events 
      (P = 0.67).
CI  - Copyright (c) 2021 Elsevier Inc. All rights reserved.
FAU - Thakker, Ravi A
AU  - Thakker RA
AD  - Department of Internal Medicine, University of Texas Medical Branch, Galveston, 
      TX. Electronic address: ravi.a.thakker@gmail.com.
FAU - Elbadawi, Ayman
AU  - Elbadawi A
AD  - Division of Cardiology, Baylor College of Medicine, Houston, TX.
FAU - Albaeni, Aiham
AU  - Albaeni A
AD  - Division of Cardiology, University of Texas Medical Branch, Galveston, TX.
FAU - Perez, Christopher
AU  - Perez C
AD  - Cardiovascular Institute, Baylor Scott & White - Temple, Temple, TX.
FAU - Hasan, Syed Mustajab
AU  - Hasan SM
AD  - Division of Cardiology, University of Texas Medical Branch, Galveston, TX.
FAU - Murrieta, Jose Iturrizaga
AU  - Murrieta JI
AD  - Division of Cardiology, University of Texas Medical Branch, Galveston, TX.
FAU - Almustafa, Ahmed
AU  - Almustafa A
AD  - Division of Cardiology, University of Texas Medical Branch, Galveston, TX.
FAU - Duarte, Alexander
AU  - Duarte A
AD  - Division of Pulmonary and Critical Care, University of Texas Medical Branch, 
      Galveston, TX.
FAU - Berbarie, Rafic F
AU  - Berbarie RF
AD  - Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, 
      TX.
FAU - Chatila, Khaled F
AU  - Chatila KF
AD  - Division of Cardiology, University of Texas Medical Branch, Galveston, TX.
FAU - Khalife, Wissam
AU  - Khalife W
AD  - Division of Cardiology, University of Texas Medical Branch, Galveston, TX.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20210704
PL  - Netherlands
TA  - Curr Probl Cardiol
JT  - Current problems in cardiology
JID - 7701802
RN  - EC 4.6.1.2 (Soluble Guanylyl Cyclase)
SB  - IM
MH  - *Heart Failure/drug therapy
MH  - Humans
MH  - Quality of Life
MH  - Soluble Guanylyl Cyclase/therapeutic use
MH  - Stroke Volume
EDAT- 2021/07/28 06:00
MHDA- 2022/08/10 06:00
CRDT- 2021/07/27 05:51
PHST- 2021/06/19 00:00 [received]
PHST- 2021/06/21 00:00 [accepted]
PHST- 2021/07/28 06:00 [pubmed]
PHST- 2022/08/10 06:00 [medline]
PHST- 2021/07/27 05:51 [entrez]
AID - S0146-2806(21)00139-0 [pii]
AID - 10.1016/j.cpcardiol.2021.100924 [doi]
PST - ppublish
SO  - Curr Probl Cardiol. 2022 Sep;47(9):100924. doi: 10.1016/j.cpcardiol.2021.100924. 
      Epub 2021 Jul 4.